Melanoma In Situ-Getting the Diagnosis and Prognosis Right

Anne E Cust^{1

2

3}, Richard A Scolyer^{2

4

5

6}

Affiliations

¹ The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
² Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
³ Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
⁴ Faculty of Medicine and Health, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
⁵ Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia.
⁶ Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.

Editorial

Anne E Cust et al. JAMA Dermatol. 2023.

. 2023 Jul 1;159(7):699-701.

doi: 10.1001/jamadermatol.2023.1485.

Anne E Cust^{1

2

3}, Richard A Scolyer^{2

4

5

6}

¹ The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
² Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
³ Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
⁴ Faculty of Medicine and Health, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
⁵ Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia.
⁶ Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.

No abstract available

Comment on

Risk of Mortality After a Diagnosis of Melanoma In Situ.
Patel VR, Roberson ML, Pignone MP, Adamson AS. Patel VR, et al. JAMA Dermatol. 2023 Jul 1;159(7):703-710. doi: 10.1001/jamadermatol.2023.1494. JAMA Dermatol. 2023. PMID: 37285145 Free PMC article.